Business & Economy

Shumlin jabs controversial drugmaker but holds off full punch

[B]URLINGTON — Gov. Peter Shumlin walked a fine line Thursday on controversial drugmaker Mylan — which has recently become the object of derision for the soaring price of its EpiPen — condemning its pricing practices but praising its role as a Vermont employer.

EpiPen is an injection containing epinephrine, which can reopen airways following an allergic reaction. Health Commissioner Dr. Harry Chen described it as a lifesaving drug.

Gov. Peter Shumlin addresses reporters at a news conference. Photo by Morgan True / VTDigger

Gov. Peter Shumlin addresses reporters at a news conference Thursday. Photo by Morgan True/VTDigger

Mylan, maker of the EpiPen, has come under intensifying scrutiny from Congress as its list price has jumped from $100 in 2007 to $600 currently, according to The New York Times.

Mylan CEO Heather Bresch has become America’s latest “pharmaceutical villain,” the Times reported.

During an unrelated news conference Thursday, Shumlin weighed in on the controversy, suggesting Mylan was just hewing to market forces in an industry whose practices he’s long decried. He also praised Mylan for its work in Vermont.

“We need to remember that Mylan is a great employer in Vermont, and they have very dedicated employees in St. Albans who are making some innovations that are critical to Americans’ health care,” Shumlin said.

“I also think it’s fair to say that Mylan, and every other pharmaceutical industry that I know about, is ripping off the American people, and they will do anything for profit, and this is yet another example of how broken the system is,” he said.

“I agree with Sen. (Bernie) Sanders and so many others that it’s time for Congress to figure out a way to stop having the American people make horrid, horrid choices between food on the table, sneakers for the kids and getting the lifesaving devices like EpiPen that we need to stay alive,” Shumlin added.

Pressed by reporters, Shumlin said he would communicate his concerns about Mylan to Bresch, the CEO. However, Shumlin said he does not regret the millions of dollars in state support provided to Mylan for the purchase of its St. Albans facility.

“Mylan has been a great corporate partner to Vermont, and when we had an opportunity to help rebuild downtown St. Albans, and had them expand jobs, over 100 high-paying jobs in Vermont, I continue to welcome them,” he said.

Shumlin said he spoke with Bresch after Mylan cut 60 jobs in St. Albans earlier this year — 10 percent of its workforce — and said he was told the cuts resulted from expiring patents.

Want to stay on top of the latest business news? Sign up here to get a weekly email on all of VTDigger's reporting on local companies and economic trends. And check out our new Business section here.

 

Morgan True

About Morgan

Morgan True is VTDigger's Burlington bureau chief covering the city and Chittenden County. A Seattle native, he graduated from Boston University with a Bachelor of Science in Journalism before working for several publications in Massachusetts. He came to VTDigger in December 2013 from The Brockton Daily Enterprise, where he covered government, schools and hospitals in a city of about 100,000 people. Before joining The Enterprise, he worked for The Associated Press in Concord, N.H., where he served as a relief reporter in the Statehouse. He previously worked for The Quincy (Mass.) Patriot Ledger and as an intern at the Worcester (Mass.) Telegram & Gazette.

Email: [email protected]

Follow Morgan on Twitter @true_morgan

Send us your thoughts

VTDigger is now accepting letters to the editor. For information about our guidelines, and access to the letter form, please click here.

 

Recent Stories

Thanks for reporting an error with the story, "Shumlin jabs controversial drugmaker but holds off full punch"